Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 255.50
Bid: 255.50
Ask: 259.00
Change: -1.00 (-0.39%)
Spread: 3.50 (1.37%)
Open: 260.00
High: 260.00
Low: 253.00
Prev. Close: 256.50
SYNT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Q1 Trading Update

21 Apr 2021 07:00

RNS Number : 0778W
Synthomer PLC
21 April 2021
 

 

21st April 2021

 

Synthomer plc

 

Q1 Trading Update

 

Stronger underlying trading across all divisions and continued exceptional Nitrile Latex performance

 

Synthomer plc ('Synthomer' or 'the Group') today issues a trading update for the quarter ended 31st March 2021.

 

Strong trading momentum across all businesses

 

Performance Elastomers

 

Performance Elastomers has continued to perform strongly. The positive trends experienced in our Nitrile Latex business during 2020 have continued through the first quarter of 2021 with overall performance ahead of expectations. Both volumes and unit margins were significantly ahead of prior year driven by exceptional demand as a consequence of the COVID-19 pandemic.

 

Conditions in our SBR latex business also continued to improve, with all segments except paper trading ahead of the comparative period in 2020. Following the strategic review of the European SBR network we completed the consultation in Marl (Germany) and the planned closure of the Oulu (Finland) site at the end of Q1.

 

Functional Solutions

 

Functional Solutions has seen a sustained improvement in the first quarter of 2021. Our consumer facing and industrial end markets have remained robust with our Oil and Gas business improving month on month. Volumes and unit margins were ahead of the comparative period supported by the acquisition of and synergies from OMNOVA and the introduction of low cost capacity in Europe and the US to drive organic growth in differentiated applications.

 

Industrial Specialities and Acrylate Monomers

 

Industrial Specialities also had a good start to the year with activity levels and unit margins significantly ahead of prior year in all major segments including automotive and consumer facing markets. Acrylate Monomers likewise benefitted from improved demand and industry supply issues resulting in a significant uplift in profitability.

 

Reducing Leverage

 

The strong trading performance and cash generation has resulted in a further reduction in proforma net debt:EBITDA to 1.2x at 31st March 2021 with anticipated leverage of less than 1.0x expected by 30th June 2021 (31st December 2020: 1.8x).

 

 

Positive outlook: strong trading increases FY EBITDA expectations

 

Whilst macroeconomic conditions remain uncertain given the ongoing COVID-19 pandemic, we are encouraged by a further strengthening of underlying trading conditions and the strong performances across all our divisions during Q1.

 

Accordingly, the Board now expects 2021 EBITDA to be in excess of £450m reflecting a further rise in the one off profitability of our Nitrile Latex business and the strengthening of the underlying trading conditions. Our expectation that the Nitrile Latex business will return to more normalised levels in 2022 remains unchanged.

 

Conference call

The company will hold a conference call for investors and analysts at 0800 BST today:

 

Dial in number:

UK (Toll free) 0800 640 6441

UK (Local) 020 3936 2999

United States (Local) 1 646 664 1960

All other locations +44 20 3936 2999

 

Access code: 921802

 

 

-ENDS-

 

Further information:

 

Calum MacLean, Chief Executive Officer

Steve Bennett, Chief Financial Officer Tel: +44 1279 436211

Tim Hughes, President, Corporate Development

 

Charles Armitstead/ Matt Denham, Teneo Tel: +44 7703 330 269/ +44 7825 735596

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTIMMATMTTTBAB
Date   Source Headline
12th Aug 20087:00 amRNSSale Completion
5th Aug 20089:42 amRNSBlocklisting Interim Review
1st Aug 200812:03 pmRNSHolding(s) in Company
21st Jul 20087:00 amRNSDisposal
27th Jun 20087:00 amRNSSale Completion
26th Jun 200810:17 amRNSHolding(s) in Company
18th Jun 200811:44 amRNSHolding(s) in Company
17th Jun 200810:12 amRNSDirector/PDMR Shareholding
16th Jun 20085:14 pmRNSDirector/PDMR Shareholding
16th Jun 200810:33 amRNSDirector/PDMR Shareholding
2nd Jun 20082:57 pmRNSBlocklisting Interim Review
30th May 20082:37 pmRNSSale Completion
15th May 20084:17 pmRNSResult of AGM
15th May 20087:00 amRNSTrading Update
9th May 20081:44 pmRNSHolding(s) in Company
24th Apr 20083:00 pmRNSAnnual Information Update
14th Apr 20084:43 pmRNSAnnual Report and Accounts
8th Apr 20089:55 amRNSDirector/PDMR Shareholding
7th Apr 20084:30 pmRNSHolding(s) in Company
14th Mar 200811:48 amRNSDirector/PDMR Shareholding
14th Mar 200811:46 amRNSDirector/PDMR Shareholding
12th Mar 20087:00 amRNSFinal Results
11th Feb 20082:40 pmRNSBlocklisting Interim Review
11th Feb 20087:01 amRNSDisposal
14th Dec 20077:00 amRNSPre-close Trading Statement
30th Nov 20073:37 pmRNSBlocklisting Interim Review
28th Nov 20072:46 pmRNSHolding(s) in Company
22nd Nov 20074:25 pmRNSDirector/PDMR Shareholding
24th Sep 200710:00 amRNSGroup Finance Director
6th Sep 20077:01 amRNSInterim Results
21st Aug 20077:00 amRNSBoard Appointments
14th Aug 20079:30 amRNSHolding(s) in Company
8th Aug 200712:16 pmRNSHolding(s) in Company
1st Aug 20077:01 amRNSPlant reorganisation
24th Jul 20072:05 pmRNSHolding(s) in Company
20th Jul 20073:50 pmRNSHolding(s) in Company
13th Jul 200712:47 pmRNSHolding(s) in Company
22nd Jun 200711:16 amRNSHolding(s) in Company
1st Jun 200711:25 amRNSBlocklisting Interim Review
1st Jun 20077:01 amRNSDivisional restructuring
29th May 20072:44 pmRNSHolding(s) in Company
17th May 20074:41 pmRNSResult of AGM
17th May 20077:01 amRNSAGM Statement
15th May 20074:29 pmRNSAnnual Report and Accounts
20th Apr 20079:40 amRNSAnnual Information Update
19th Apr 200712:47 pmRNSHolding(s) in Company
10th Apr 20075:26 pmRNSDirectorate Change
29th Mar 20074:37 pmRNSHolding(s) in Company
22nd Mar 200712:30 pmRNSDirectorate Change
12th Mar 20071:05 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.